| BIOGEN INC. DL -,0005 | 209.700 / 0.00% |
| Date/Time | 08/22 / 13:43 |
| Chg. / Chg.(%) | 0.000 / 0.00% |
| Bid | - / 100 |
| Ask | - / 100 |
| Open | 209.700 |
| Previous Close | 209.700 |
| High | 209.700 |
| Low | 209.700 |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | 5 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | gettex |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Frankfurt | 209.4500 |  |
10 |
| TradeGate | 209.300 | |
10 |
| IEX | 233.83 | |
2 |
| München | 209.40 | |
1 |
| Vienna Globa.. | 210.40 | |
0 |
| Hamburg | 209.40 | |
0 |
| Düsseldorf | 209.10 | |
0 |
| Berlin | 210.45 | |
0 |
| Hannover | 209.40 | |
0 |
| Lang & Schwa.. | 210.200 | |
|
| gettex | 209.700 | |
|
| Stuttgart | 209.450 | |
|
| NASDAQ | 233.1800 | |
807,490 |
| Cboe US | 233.18 | 42,544 | |
| Xetra | 209.95 | 65 | |
| London Inter.. | 232.65 | 9 | |
| SIX Swiss Ex.. | 232.00 | ||
| Mexico | 4,569.20 | 200 |
News
- Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
08/20/2019 / 13:30 - GlobeNewswire - Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
07/30/2019 / 13:30 - GlobeNewswire - Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors
07/25/2019 / 14:30 - GlobeNewswire - Biogen's GAAP diluted EPS in Q2 increases 88% YoY
07/23/2019 / 12:35 - TeleTrader - Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
07/01/2019 / 13:30 - GlobeNewswire
Personal area
Real-timeClick on 
to activate push quotes.
to activate push quotes.